Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Researchers analyzed the use of inotuzumab as a bridging therapy prior to CAR T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. They concluded that among the 24 patients analyzed, inotuzumab may effectively reduce tumor burden and CAR-T expansion without compromising survival outcomes.